Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.

Dynamic hyperinflation (DH) is a major pathophysiologic consequence of airflow limitation during exercise in patients with chronic obstructive pulmonary disease (COPD) and an important contributing factor to breathlessness. In this study we aimed to examine the effect of inhaled beta agonist therapy on DH during exercise in these patients and the relationship between changes in DH and breathlessness. In 13 COPD patients (mean age 65.1 +/- 2.0, FEV1 1.20 +/- 0.17, FEV1/FVC 40 +/- 3) we measured pulmonary function tests, exercise breathlessness by Borg score, and exercise flow volume and pressure volume loops on two separate days. Prior to testing, patients randomly received inhaled placebo or albuterol on the first test day and the alternative medication on the second test day. From measurements of exercise inspiratory capacity (IC), we calculated the end-expiratory and end-inspiratory lung volumes (EELV, EILV). We used esophageal pressure recordings to measure peak inspiratory esophageal pressure (Pesins) during exercise and this was related to the maximal capacity for pressure generation taking into account lung volume and airflow changes (Pcapi). Bronchodilator caused significant increase in both FEV1 and FVC (+0.23 and +0.51, p<0.01). Comparisons of breathlessness, exercise volumes, and pressures were made at the highest equivalent work load. There was a significant reduction in the peak exercise EELV/TLC (80 +/- 0.02% to 76 +/- 0.02%, p<0.05) while the peak EILV/TLC decreased by 2% (97 +/- 1% to 95 +/- 1%, p<0.05). The peak Pesins/Pcapi decreased (0.79 +/- 0.10 to 0.57 +/- 0.05, p<0.05), and the Pcapi - Pesins increased (7.4 +/- 3 to 13.0 +/- 3 cm H2O, p<0.05). There was significant improvement in neuroventilatory coupling for volume change (Pesins/Pcapi/VT/TLC 5.45 +/- 0.5 to 3.25 +/- 1.0, p<0.05). There was a significant reduction in breathlessness as measured by Borg score (4.5 +/- 0.7 to 3.1 +/- 0.5, p<0.05) and there was a significant correlation between delta Borg and delta EILV/TLC (r=0.771, p<0.01) with a trend for Pesins/Pcapi/VT/TLC (r=0.544, p=0.067). There was also a significant correlation between delta EELV/TLC and delta Pesins/Pcapi/VT/TLC (r=0.772, p<0.01). The relationships between delta Borg, delta resting volumes, and flow rates were not significant. We conclude that in patients with COPD, inhaled bronchodilator reduces exercise DH and improves inspiratory pressure reserve and neuroventilatory coupling. Changes in DH and neuroventilatory coupling were the main determinants of reduced breathlessness.

[1]  D. O’Donnell,et al.  Breathlessness in patients with chronic airflow limitation. Mechanisms and management. , 1994, Chest.

[2]  M. Lougheed,et al.  Breathlessness during acute bronchoconstriction in asthma. Pathophysiologic mechanisms. , 1993, The American review of respiratory disease.

[3]  D. O’Donnell,et al.  Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. , 1993, The American review of respiratory disease.

[4]  J. Moxham,et al.  The effects of beta 2-agonists and caffeine on respiratory and limb muscle performance. , 1993, The European respiratory journal.

[5]  M. Younes.  Determinants of thoracic excursions during exercise , 1991 .

[6]  R. Viggiano,et al.  Effect of mild-to-moderate airflow limitation on exercise capacity. , 1991, Journal of applied physiology.

[7]  S. Gottfried,et al.  Effect of CPAP on respiratory effort and dyspnea during exercise in severe COPD. , 1990, Journal of applied physiology.

[8]  G H Guyatt,et al.  The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. , 1990, Annals of internal medicine.

[9]  M. Aubier,et al.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. , 1989, The New England journal of medicine.

[10]  H. Chrystyn,et al.  Dose response relation to oral theophylline in severe chronic obstructive airways disease. , 1988, BMJ.

[11]  R. Irwin,et al.  Predicting response to bronchodilator therapy in chronic obstructive pulmonary disease. , 1988, Archives of internal medicine.

[12]  J. Moxham.  Aminophylline and the respiratory muscles: an alternative view. , 1988, Clinics in chest medicine.

[13]  M. Younes,et al.  Effect of continuous positive airway pressure on respiratory sensation in patients with chronic obstructive pulmonary disease during submaximal exercise. , 1988, The American review of respiratory disease.

[14]  Buist As.  Standardization of spirometry. , 1987 .

[15]  N. Jones,et al.  Breathlessness and exercise in patients with cardiorespiratory disease. , 2015, The American review of respiratory disease.

[16]  S. Cohen,et al.  The effect of maintenance theophylline therapy on lung work in severe chronic obstructive pulmonary disease while standing and walking. , 1984, The American review of respiratory disease.

[17]  L. A. Engel,et al.  Chest wall mechanics during exercise in patients with severe chronic air-flow obstruction. , 1984, The American review of respiratory disease.

[18]  G. Borg.  Psychophysical bases of perceived exertion. , 1982, Medicine and science in sports and exercise.

[19]  N. Jones,et al.  Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. , 1980, Journal of applied physiology: respiratory, environmental and exercise physiology.

[20]  J. Ramsdell,et al.  Determination of bronchodilation in the clinical pulmonary function laboratory. Role of changes in static lung volumes. , 1979, Chest.

[21]  R. Hyatt,et al.  Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease. , 1971, The Journal of clinical investigation.